The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic

References

• Levy BT, Graber MA. Respiratory syncytial virus infection in infants and young children. J Fam Pract 1997;45:473-81.
   PubMed Web of Science ®Google Scholar
• Ottolini MG, Hemming VG. Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery. Drugs 1997;54: 867-84.
   PubMed Web of Science ®Google Scholar
• Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52.
   PubMed Web of Science ®Google Scholar
• Banerji A. High rates of hospitalisation for bronchiolitis in Inuit children on Baffin Island. Int J Circumpolar Health 2001;60:375-9.
   PubMedGoogle Scholar
• Banerji A, Bell A, Mills EL, Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 2001;164:1847-50.
   PubMed Web of Science ®Google Scholar
• Carson JB, Postl BD, Spady D, Lower respiratory tract infections in Inuit infants on Baffin Island. Int J Circumpolar Health 2001;84:226-8.
   Google Scholar
• Young M, Kandola K, Mitchell R, Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and the Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health 2007;12:563-6.
   PubMed Web of Science ®Google Scholar
• Hall CB. Respiratory syncytial virus. In: Feigin R, Cherry J , eds. Infectious Diseases. Philadelphia: W.B. Saunders, 1998.
   Google Scholar
• Anderson LJ, Hierholzer JC, Tsou C, Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985;151:626-33.
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The Impact-RSV Study Group [see comments]. Pediatrics 1998;102:531-7.
   PubMed Web of Science ®Google Scholar
• Canadian Pediatric Society. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999;4(7):474-80.
   PubMedGoogle Scholar
• Banerji A, Lanctôt KL, Paes BA, Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28:702-6.
   PubMed Web of Science ®Google Scholar
• Banerji A, Greenberg D, White LF, Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case-control study. Pediatr Infect Dis J 2009;28:697-701.
   PubMed Web of Science ®Google Scholar
• Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997;99:93-9.
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang EE, Law BJ, Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131:113-17.
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Masoud ST, Paes BA, The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-7.
   PubMed Web of Science ®Google Scholar
• Creery D, Lyer P, Samson L, Costs associated with infant bronchiolitis in the Baffin region of Nunavut. Int J Circumpolar Health 2005;64:38-45.
   PubMedGoogle Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25(1): 55-71.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
   PubMed Web of Science ®Google Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531-7.
   Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150-6.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada [3rd edn]. Ottawa, 2006.
   Google Scholar
• Greenough A, Alexander J, Burgess S, Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89:673-8.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R, Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137-41.
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ, Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-5.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Clinical Growth Charts. [cited 2008; Available from: http://www.cdc.gov/growthcharts/clinical_charts.htm.
   Google Scholar
• Statistics Canada: Canada's National Statistical Agency. Earnings, average weekly, by province and territory (Table). In 2007.
   Google Scholar
• Statistics Canada: Canada's National Statistical Agency. The Daily: Labour Force Survey. 2007 [cited; Available from: http://www.statcan.ca/Daily/English/071207/d071207a.htm.
   Google Scholar
• Orr P, McDonald S, Milley D, Bronchiolitis in Inuit children from a Canadian central Arctic community, 1995-1996. Int J Circumpolar Health 2001;60:649-58.
   PubMedGoogle Scholar
• Healey S, Plaza D, Qayyum A, Nunavut report on comparable health indicators. In: Department of Health and Social Services, Government of Nunavut, editors, 2004.
   Google Scholar
• Briggs A, Sculpher MJ, Claxton K. Decision Modelling for Health Economic Evaluation. Handbooks in Health Economic Evaluation, volume 1. Oxford: Oxford University Press, 2006.
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review Database. [cited July 31, 2008]; Available from: http://www.cadth.ca/index.php/en/cdr/search? &status=complete&order_field=drug_name.
   Google Scholar
• Greenough A, Cox S, Alexander J, Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463-8.
   PubMed Web of Science ®Google Scholar
• Perez-Yarza EG, Moreno A, Lazaro P, The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007;26:733-9.
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Redding GJ, Lewis TC, Sequelae of severe respiratory syncytial virus infection in infancy and early childhood among Alaska Native children. Pediatrics 2003;112:285-90.
   PubMed Web of Science ®Google Scholar
• Singleton R, Morris A, Redding G, Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29:182-7.
   PubMed Web of Science ®Google Scholar
• Fleshman JK, Wilson JF, Cohen JJ. Bronchiectasis in Alaska native children. Arch Environ Health 1968;17:517-23.
   PubMed Web of Science ®Google Scholar
• Redding G, Singleton R, Lewis T, Early radiographic and clinical features associated with bronchiectasis in children. Pediatr Pulmonol 2004;37:297-304.
   PubMed Web of Science ®Google Scholar
• Hemmelgarn B, Ernst P. Airway function among Inuit primary school children in far northern Quebec. Am J Respir Crit Care Med 1997;156:1870-5.
   PubMed Web of Science ®Google Scholar
• Chandran A, Millar EV, Weatherholtz R, Safety and efficacy of motavizumab in the prevention of RSV disease in healthy infants. In: Pediatric Academic Societies, 4 May 2008; Hawaii. Abstract 4460.5.
   Google Scholar
• Gooding J, Millage A, Rye A-K, The cost and safety of multidose use of palivizumab vials. Clin Pediatr (Phila) 2007;47: 160-3.
   PubMed Web of Science ®Google Scholar
• Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch Dis Child 2006;91:717
   PubMed Web of Science ®Google Scholar